Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
Portfolio Pulse from
Five major pharmaceutical companies, Merck (MRK), Pfizer (PFE), Eli Lilly (LLY), Amgen (AMGN), and Bristol-Myers Squibb (BMY), are set to release their Q4 2024 earnings results later this week. Investors are keen to see if these companies will surpass earnings forecasts.
February 03, 2025 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amgen is about to release its Q4 2024 earnings. The market is keen to see if it will exceed forecasts.
Amgen's earnings announcement is significant as it may impact stock prices based on whether it meets or exceeds expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Bristol-Myers Squibb is set to announce its Q4 2024 earnings. Investors are eager to see if it will surpass forecasts.
Bristol-Myers Squibb's earnings release is crucial for investors as it could influence stock performance based on the results.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Eli Lilly is set to report its Q4 2024 earnings. Investors are watching closely to see if it will beat forecasts.
Eli Lilly's earnings release is important for investors as it could affect stock prices depending on the results.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Merck is set to release its Q4 2024 earnings later this week. Investors are watching to see if it will surpass forecasts.
Merck's upcoming earnings release is significant for investors as it could impact stock prices depending on whether it meets or exceeds forecasts.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Pfizer is preparing to announce its Q4 2024 earnings. The market is eager to see if it will exceed expectations.
Pfizer's earnings announcement is crucial as it may influence investor sentiment and stock performance based on the results.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80